Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
PMV Pharmaceuticals, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
PMV Pharmaceuticals held its 2026 Annual Meeting of Stockholders on June 4, 2026, where shareholders elected David H. Mack, Ph.D. and Laurie Stelzer as Class III Directors to serve until 2029, demonstrating continued board stability and governance continuity.
Key Takeaways
David H. Mack, Ph.D. received 15,693,907 votes in favor for Class III Director election
Laurie Stelzer received 11,261,111 votes in favor for Class III Director election
2 more takeaways